| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| Other Sizes |
|
Purity: ≥98%
Trifluridine (also known as trifluorothymidine; FTD; NSC-529182; NSC-75520; NSC529182; NSC75520; Viroptic), an inhibitor of the thymidylate synthase and DNA synthesis, is an approved anti-herpesvirus antiviral agent/medications used mainly for treating infections in the eye. It is an analogue of nucleosides, idoxuridine, and a modified form of deoxyuridine that is sufficiently similar to be integrated into the replication of viral DNA; however, base pairing is prevented by the addition of the -CF3 group to the uracil component. It is one of the two parts of TAS-102, an experimental anti-cancer medication.
| Targets |
HSV-2; HSV-1; Nucleoside Antimetabolite/Analog; Thymidylate Synthase
|
||
|---|---|---|---|
| ln Vitro |
|
||
| ln Vivo |
|
||
| Animal Protocol |
|
||
| References |
| Molecular Formula |
C10H11F3N2O5
|
|
|---|---|---|
| Molecular Weight |
296.2
|
|
| Exact Mass |
296.06
|
|
| Elemental Analysis |
C, 40.55; H, 3.74; F, 19.24; N, 9.46; O, 27.01
|
|
| CAS # |
70-00-8
|
|
| Related CAS # |
|
|
| Appearance |
Solid powder
|
|
| SMILES |
C1[C@@H]([C@H](O[C@H]1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O
|
|
| InChi Key |
VSQQQLOSPVPRAZ-RRKCRQDMSA-N
|
|
| InChi Code |
InChI=1S/C10H11F3N2O5/c11-10(12,13)4-2-15(9(19)14-8(4)18)7-1-5(17)6(3-16)20-7/h2,5-7,16-17H,1,3H2,(H,14,18,19)/t5-,6+,7+/m0/s1
|
|
| Chemical Name |
1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-(trifluoromethyl)pyrimidine-2,4-dione
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.44 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.44 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (8.44 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3761 mL | 16.8805 mL | 33.7610 mL | |
| 5 mM | 0.6752 mL | 3.3761 mL | 6.7522 mL | |
| 10 mM | 0.3376 mL | 1.6880 mL | 3.3761 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT04737187 | Active Recruiting |
Drug: Trifluridine/Tipiracil Drug: Bevacizumab |
Refractory Metastatic Colorectal Cancer |
Taiho Oncology, Inc. | November 25, 2020 | Phase 3 |
| NCT03992456 | Active Recruiting |
Biological: Panitumumab Drug: Regorafenib |
Metastatic Colorectal Carcinoma Stage III Colon Cancer AJCC v8 |
Academic and Community Cancer Research United |
April 24, 2020 | Phase 2 |
| NCT03981614 | Active Recruiting |
Drug: Palbociclib Drug: Binimetinib |
Unresectable Carcinoma Metastatic Colorectal Carcinoma |
Academic and Community Cancer Research United |
October 29, 2019 | Phase 2 |
| NCT05198934 | Active Recruiting |
Drug: Trifluridine and Tipiracil Drug: Regorafenib |
Colorectal Cancer (CRC) | Amgen | April 19, 2022 | Phase 3 |
| NCT05608044 | Active Recruiting |
Drug: Botensilimab Drug: Balstilimab |
Metastatic Colorectal Cancer | Agenus Inc. | November 30, 2022 | Phase 2 |
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
